Influenza - Time to target the host?

New England Journal of Medicine

Volumn 369, Issue 2, 2013, Pages 191-193

  Baillie, J Kenneth ^a,b   Digard, Paul ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; FISH OIL; PERAMIVIR; PROTECTIN D1; UNCLASSIFIED DRUG; VIRUS RNA;

CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CRITICALLY ILL PATIENT; DRUG MECHANISM; EDITORIAL; HUMAN; INFLUENZA; INFLUENZA VIRUS; INTENSIVE CARE UNIT; LIPIDOMICS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS REPLICATION;

EID: 84880291364     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr1304414     Document Type: Article

References (5)

1. Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012;156:512-24.
2. Morita M, Kuba K, Ichikawa A, et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell 2013;153:112-25.
3. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007;6:231-48. (Pubitemid 46344627)
4. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-61. (Pubitemid 351595216)
5. Horby P, Nguyen NY, Dunstan SJ, Baillie JK. The role of host genetics in susceptibility to influenza: a systematic review. PLoS One 2012;7(3):e33180.